13th International Conference On Thalassemia & Hemoglobinopathies
15th TIF International Conference For Parents & Patients
20th – 23rd October 2013 - Abu Dhabi - UAE
Novartis Oncology has emerged as a global leader in oncology through targeted research and open partnership in the pursuit of new therapies capable of transforming outcomes for people with cancer.
ApoPharma is an innovative drug development company specializing in the discovery, development and commercialization of innovative medications, with a key focus on iron metabolism disorders; specifically, the development of drugs for the treatment of iron overload.
EMAL is a state-of-the-art aluminium smelter complex supplying the world with high quality metal. The advanced smelter in Al Taweelah currently uses DX Reduction Cell Technology to produce 800,000 tonnes of aluminium annually.
Thalassemia is one of the most common genetic blood disorders known to mankind. Estimates indicate that at least 12 children suffering from Thalassemia are born every hour around the world and that with the presence of more than 490 million carriers of the genetic disorder worldwide, presents significant pressure on the medical resources, social and economic development of many countries due to the lack of presence of a comprehensive prevention program for Thalassemia.
His Highness Sheikh Sultan Bin Khalifa Al Nahyan Humanitarian & Scientific Foundation is structured to deliver the objectives to serve the UAE community in specific and the global community in general. Under the supreme authority of H.H Dr. Sheikh Sultan Bin Khalifa Bin Zayed Al Nahyan the Foundation aims to achieves its objectives through its three divisions & the Regional Collaborating office of Thalassemia International Federation.
Regional Collaborating Office of Thalassaemia International Federation is a joint venture between Thalassaemia International Federation (TIF) and H. H. Sheikh Sultan Bin Khalifa Al Nahyan Humanitarian & Science Foundation.
Thalassaemia International Federation (TIF) is a non-profit, non-governmental patient-driven organisation founded in 1986 and working in official relations with the World Health Organization (WHO) since 1996.
Hybribio is an innovative company in the field of life sciences, endeavoring to apply assay technologies to commercial use. With the commitment to the betterment of human healthcare, Hybribio is dedicated to technology breakthrough and product innovation.
Fresenius Kabi is a leading international health care company focusing on products for the therapy and care of critically and chronically ill patients. Our product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the medical devices for administering these products.
Celgene is Building a Preeminent Global Biopharmaceutical Company Focused on the Discovery, Development and Commercialization of Innovative Therapies for Unmet Medical Needs in Cancer and Immune-Inflammatory Diseases.
Cerus’ INTERCEPT Blood System reduces the risk of transfusion- transmitted disease by inactivating a broad range of viruses, bacteria and parasites that may be present in donated blood.
Trinity Biotech manufacture industry leading instrumentation for the rapid & accurate analysis of diabetic HbA1c and the detection of abnormal haemoglobins.
Connect with us